Treats relapsing forms of multiple sclerosis (MS). ANDA 209555, held by Natco. Teriflunomide.
As of Nov 16, 2026, ANDA 209555 (Teriflunomide), held by Natco, was first approved by FDA on May 15, 2023, with 0 approved supplements and 0 published complete response letters.
Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 15, 2023 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters